Literature DB >> 14516823

Polymicrobial keratitis secondary to Burkholderia ambifaria, enterococcus, and staphylococcus aureus in a patient with herpetic stromal keratitis.

Alice Y Matoba1.   

Abstract

PURPOSE: To report polymicrobial keratitis in a patient with herpetic stromal keratitis. The initial infecting organism, Burkholderia ambifaria, has not previously been reported to cause microbial keratitis.
METHODS: Clinical evaluation and corneal culture were performed.
RESULTS: A 59-year-old-man undergoing topical corticosteroid therapy for herpes simplex stromal keratitis developed corneal infection with B. ambifaria. The organism was reisolated 12 days after initiation of hourly therapy with topical levofloxacin 0.5%. At reculture Staphylococcus aureus and Enterococcus spp. were also isolated. The addition of topical amikacin and vancomycin led to resolution of the microbial keratitis.
CONCLUSIONS: Burkholderia ambifaria infected a compromised cornea, exhibited an unusual sensitivity profile, and remained viable after 12 days of therapy with an antibiotic to which it was sensitive by in vitro tests.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14516823     DOI: 10.1016/s0002-9394(03)00395-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Polymicrobial infection and the eye.

Authors:  S Tuft
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

2.  Clinico-microbiological profile of Burkholderia cepacia keratitis: a case series.

Authors:  Ming-Chih Ho; Eugene Yu-Chuan Kang; Lung-Kun Yeh; David H K Ma; Hsin-Chiung Lin; Hsin-Yuan Tan; Hung-Chi Chen; Ching-Hsi Hsiao
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-01-07       Impact factor: 3.944

3.  Multi-drug resistant Burkholderia cepacia keratitis following laser in situ keratomileusis complicated by interface fluid syndrome.

Authors:  Vaibhav Kanduri; Bhagyashree Madduri; Nitin Mohan; Merle Fernandes
Journal:  Indian J Ophthalmol       Date:  2020-07       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.